The Driver and Vehicle Licensing Agency (DVLA) takes the protection of the data it holds very seriously and has robust measures in place to protect it. The request from ParkTrade Europe is receiving careful attention and an outcome will be provided as soon as the consideration of these matters is complete.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4584", "label" : {"_value" : "Biography information for Baroness Sugg"} } , "answeringMemberPrinted" : {"_value" : "Baroness Sugg"} , "dateOfAnswer" : {"_value" : "2018-10-17", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-10-17T15:12:04.677Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "27"} , "answeringDeptShortName" : {"_value" : "Transport"} , "answeringDeptSortName" : {"_value" : "Transport"} , "date" : {"_value" : "2018-10-11", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Driver and Vehicle Licensing Agency: Information Sharing"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government whether they intend to extend the DVLA's Data Sharing Strategy to ParkTrade Europe AB and others who legitimately seek information to allow authorities in Europe to recover monies due to them from UK registered vehicle owners.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/891", "label" : {"_value" : "Biography information for Lord Kirkhope of Harrogate"} } , "tablingMemberPrinted" : [{"_value" : "Lord Kirkhope of Harrogate"} ], "uin" : "HL10618"} , {"_about" : "http://data.parliament.uk/resources/985012", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/985012/answer", "answerText" : {"_value" : "
Skills for Care publishes data on the adult social care workforce. They estimate that 8% of roles in the adult social care sector remained vacant in 2017/18, this gives an average of approximately 110,000 vacancies at any one time. Projections show the number of adult social care jobs required will increase by 40% (650,000 jobs) to around 2.55 million jobs by 2035.<\/p>
The Government is aware that our challenge, working alongside our partners in the adult social care sector, is to ensure the workforce has the right number of people to meet increasing demands, with the right skills, knowledge and values to deliver quality, compassionate care. We are looking to address the broader challenges around staff recruitment and retention in the social care market, and consulted on this issue earlier on the year. The evidence provided in the consultation responses will inform our Green Paper on the future of adult social care, with a strategy for its workforce, later this year.<\/p>
In addition, the Department has announced the launch of a new adult social care recruitment campaign this autumn. This will raise the profile of the sector and help build awareness of the rich variety of roles careers on offer and attract the right people, with the right values, to deliver the very best care.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"} } , "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"} , "dateOfAnswer" : {"_value" : "2018-10-17", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-10-17T15:07:06.35Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-10-10", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Care Workers"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what estimate they have made of the number of adult social care workers required in England in the next ten years; what is the current shortfall in the number of adult social care workers in England; and what action they are taking to address that shortfall.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/259", "label" : {"_value" : "Biography information for The Marquess of Lothian"} } , "tablingMemberPrinted" : [{"_value" : "The Marquess of Lothian"} ], "uin" : "HL10555"} , {"_about" : "http://data.parliament.uk/resources/985013", "AnsweringBody" : [{"_value" : "Home Office"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/985013/answer", "answerText" : {"_value" : "
The available information is given below.<\/p>
Family reunion applications from dependants of those with refugee status or humanitarian protection in the UK (made under Part 11 of the Immigration Rules) are included in the \u2018Family: Other\u2019 category within the published Home Office \u2018Immigration Statistics\u2019 visa tables, latest edition at, https://www.gov.uk/government/publications/immigration-statistics-year-ending-june-2018/list-of-tables#visas<\/a>.<\/p> The vast majority of the \u2018Family: Other\u2019 category relate to family reunion and hence the published figures provide a good indication of trends for family reunion cases.<\/p> The table below provides the latest data:<\/p> 'Family: Other' entry clearance visa applications and outcomes: 2010 to 2017<\/strong><\/p> Year<\/strong><\/p><\/td> Applications<\/strong><\/p><\/td> Resolved<\/strong><\/p><\/td> Granted<\/strong><\/p><\/td> %<\/strong><\/p><\/td> Refused<\/strong><\/p><\/td> Withdrawn/Lapsed<\/strong><\/p><\/td><\/tr> 2010<\/p><\/td> 6,111<\/p><\/td> 6,654<\/p><\/td> 4,887<\/p><\/td> 73%<\/p><\/td> 1,664<\/p><\/td> 103<\/p><\/td><\/tr> 2011<\/p><\/td> 5,143<\/p><\/td> 5,536<\/p><\/td> 4,306<\/p><\/td> 78%<\/p><\/td> 1,093<\/p><\/td> 137<\/p><\/td><\/tr> 2012<\/p><\/td> 5,135<\/p><\/td> 5,318<\/p><\/td> 3,710<\/p><\/td> 70%<\/p><\/td> 1,479<\/p><\/td> 129<\/p><\/td><\/tr> 2013<\/p><\/td> 6,064<\/p><\/td> 6,108<\/p><\/td> 4,211<\/p><\/td> 69%<\/p><\/td> 1,797<\/p><\/td> 100<\/p><\/td><\/tr> 2014<\/p><\/td> 5,639<\/p><\/td> 6,658<\/p><\/td> 4,596<\/p><\/td> 69%<\/p><\/td> 1,931<\/p><\/td> 131<\/p><\/td><\/tr> 2015<\/p><\/td> 8,477<\/p><\/td> 8,283<\/p><\/td> 4,887<\/p><\/td> 59%<\/p><\/td> 3,267<\/p><\/td> 129<\/p><\/td><\/tr> 2016<\/p><\/td> 8,610<\/p><\/td> 9,620<\/p><\/td> 6,098<\/p><\/td> 63%<\/p><\/td> 3,472<\/p><\/td> 50<\/p><\/td><\/tr> 2017<\/p><\/td> 7,439<\/p><\/td> 7,543<\/p><\/td> 5,237<\/p><\/td> 69%<\/p><\/td> 2,253<\/p><\/td> 53<\/p><\/td><\/tr><\/tbody><\/table> <\/strong> Notes:<\/strong> Applications made in a given year may be resolved (granted, refused, withdrawn or lapsed) in a later year.<\/p><\/td><\/tr> Source:<\/strong> Home Office 'Immigration Statistics, year ending June 2018', Visas data tables volume 1, table vi_01_q.<\/p><\/td><\/tr><\/tbody><\/table> <\/p> :<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4311", "label" : {"_value" : "Biography information for Baroness Williams of Trafford"}
}
, "answeringMemberPrinted" : {"_value" : "Baroness Williams of Trafford"}
, "dateOfAnswer" : {"_value" : "2018-10-17", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-10-17T12:40:14.1Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "1"}
, "answeringDeptShortName" : {"_value" : "Home Office"}
, "answeringDeptSortName" : {"_value" : "Home Office"}
, "date" : {"_value" : "2018-10-10", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asylum: Families"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty's Government how many applications they have received for UK visas for family settlement to reunite with a partner or parent who is in the UK as a refugee or with humanitarian protection in each year since 2010; and of those, how many have been granted.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/259", "label" : {"_value" : "Biography information for The Marquess of Lothian"}
}
, "tablingMemberPrinted" : [{"_value" : "The Marquess of Lothian"}
], "uin" : "HL10556"}
, {"_about" : "http://data.parliament.uk/resources/985031", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/985031/answer", "answerText" : {"_value" : " The Department for Education has an ongoing dialogue with Public Health England on the issue of children\u2019s speech and language development. They have formed a partnership to address the \u2018word gap\u2019 and support the speech, language and communication elements of the Healthy Child Programme. This programme of work will include training and resources for health visitors on speech, language and communication needs, incorporating evidence-based red flags on delayed early use of gesture and pointing by young children.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
}
, "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
, "dateOfAnswer" : {"_value" : "2018-10-17", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-10-17T15:01:17.737Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-10-10", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Special Educational Needs: Speech and Language Disorders"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty's Government what discussions they have had with Public Health England about providing practitioners with evidence-based red flags that indicate communication and language concerns at each of the statutory review points that are part of the next review of the Healthy Child Programme.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/3744", "label" : {"_value" : "Biography information for Lord Ramsbotham"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Ramsbotham"}
], "uin" : "HL10574"}
, {"_about" : "http://data.parliament.uk/resources/985057", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/985057/answer", "answerText" : {"_value" : " The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of nusinersen (Spinraza) for the treatment of spinal muscular atrophy (SMA).<\/p> NHS England has published an Interim Policy Statement Urgent Clinical Commissioning Policy Statement: Nusinersen for genetically confirmed Spinal Muscular Atrophy (SMA) type 1 for eligible patients under the Expanded Access Programme (EAP) <\/em>determining the circumstances in which patients will be supported to access nusinersen through the EAP scheme sponsored by Biogen, the manufacturer of nusinersen. A copy is attached. The policy statement enables patients with type 1 SMA to access nusinersen in advance of NICE\u2019s guidance.<\/p> In the absence of final guidance from NICE, clinicians can apply to NHS England for funding in exceptional cases through the individual funding request process.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
}
, "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
, "attachment" : {"_about" : "http://data.parliament.uk/resources/985057/answer/attachment/1", "fileName" : {"_value" : "nusinersen-for-genetically-confirmed-spinal-muscular-atrophy.pdf"}
, "title" : "Commissioning policy statement nusinersen"}
, "dateOfAnswer" : {"_value" : "2018-10-17", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "HL10601"}
, {"_value" : "HL10602"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-10-17T15:08:15.027Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-10-10", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Spinal Muscular Atrophy: Drugs"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty's Government what guidance is provided to NHS Trusts about the use of medication not approved by NICE to treat spinal muscular atrophy (SMA).", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1744", "label" : {"_value" : "Biography information for Viscount Waverley"}
}
, "tablingMemberPrinted" : [{"_value" : "Viscount Waverley"}
], "uin" : "HL10600"}
, {"_about" : "http://data.parliament.uk/resources/985058", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/985058/answer", "answerText" : {"_value" : " The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of nusinersen (Spinraza) for the treatment of spinal muscular atrophy (SMA).<\/p> NHS England has published an Interim Policy Statement Urgent Clinical Commissioning Policy Statement: Nusinersen for genetically confirmed Spinal Muscular Atrophy (SMA) type 1 for eligible patients under the Expanded Access Programme (EAP) <\/em>determining the circumstances in which patients will be supported to access nusinersen through the EAP scheme sponsored by Biogen, the manufacturer of nusinersen. A copy is attached. The policy statement enables patients with type 1 SMA to access nusinersen in advance of NICE\u2019s guidance.<\/p> In the absence of final guidance from NICE, clinicians can apply to NHS England for funding in exceptional cases through the individual funding request process.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
}
, "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
, "attachment" : {"_about" : "http://data.parliament.uk/resources/985058/answer/attachment/1", "fileName" : {"_value" : "nusinersen-for-genetically-confirmed-spinal-muscular-atrophy.pdf"}
, "title" : "Commissioning policy statement nusinersen"}
, "dateOfAnswer" : {"_value" : "2018-10-17", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "HL10600"}
, {"_value" : "HL10602"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-10-17T15:08:15.097Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-10-10", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Spinal Muscular Atrophy: Drugs"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty's Government what assessment they have made of making financial resources available to patients with spinal muscular atrophy (SMA) to obtain medication not approved by NICE.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1744", "label" : {"_value" : "Biography information for Viscount Waverley"}
}
, "tablingMemberPrinted" : [{"_value" : "Viscount Waverley"}
], "uin" : "HL10601"}
, {"_about" : "http://data.parliament.uk/resources/985059", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/985059/answer", "answerText" : {"_value" : " The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of nusinersen (Spinraza) for the treatment of spinal muscular atrophy (SMA).<\/p> NHS England has published an Interim Policy Statement Urgent Clinical Commissioning Policy Statement: Nusinersen for genetically confirmed Spinal Muscular Atrophy (SMA) type 1 for eligible patients under the Expanded Access Programme (EAP) <\/em>determining the circumstances in which patients will be supported to access nusinersen through the EAP scheme sponsored by Biogen, the manufacturer of nusinersen. A copy is attached. The policy statement enables patients with type 1 SMA to access nusinersen in advance of NICE\u2019s guidance.<\/p> In the absence of final guidance from NICE, clinicians can apply to NHS England for funding in exceptional cases through the individual funding request process.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
}
, "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
, "attachment" : {"_about" : "http://data.parliament.uk/resources/985059/answer/attachment/1", "fileName" : {"_value" : "nusinersen-for-genetically-confirmed-spinal-muscular-atrophy.pdf"}
, "title" : "Commissioning policy statement nusinersen"}
, "dateOfAnswer" : {"_value" : "2018-10-17", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "HL10600"}
, {"_value" : "HL10601"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-10-17T15:08:15.16Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-10-10", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Spinal Muscular Atrophy: Nusinersen"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty's Government what guidance is provided by NHS Trusts about making the drug Spinraza available through the NHS to patients with spinal muscular atrophy (SMA).", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1744", "label" : {"_value" : "Biography information for Viscount Waverley"}
}
, "tablingMemberPrinted" : [{"_value" : "Viscount Waverley"}
], "uin" : "HL10602"}
, {"_about" : "http://data.parliament.uk/resources/984249", "AnsweringBody" : [{"_value" : "Women and Equalities"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/984249/answer", "answerText" : {"_value" : " Conversion therapy is wrong and we are not willing to let it continue.<\/p> <\/p> As part of the LGBT Action Plan, we have committed to bring forward proposals to end the practice of conversion therapy in the UK. We have committed to consider all legislative and non-legislative options to prohibit promoting, offering or conducting these practices whether they are occurring in a medical, commercial or faith-based context.<\/p> <\/p> This is a complex issue that we will be approaching sensitively. We intend to engage widely before bringing forward proposals, and we will consult on the final package to ensure that the actions we take are effective and have broad support.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4311", "label" : {"_value" : "Biography information for Baroness Williams of Trafford"}
}
, "answeringMemberPrinted" : {"_value" : "Baroness Williams of Trafford"}
, "dateOfAnswer" : {"_value" : "2018-10-17", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-10-17T15:19:38.57Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "31"}
, "answeringDeptShortName" : {"_value" : "Women and Equalities"}
, "answeringDeptSortName" : {"_value" : "Women and Equalities"}
, "date" : {"_value" : "2018-10-09", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Conversion Therapy"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty's Government whether they plan to undertake any consultation before bringing forward proposals to ban gay conversion therapy; if so, which stakeholders they plan to consult; and what is the timetable.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4171", "label" : {"_value" : "Biography information for Lord Black of Brentwood"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Black of Brentwood"}
], "uin" : "HL10457"}
, {"_about" : "http://data.parliament.uk/resources/984260", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/984260/answer", "answerText" : {"_value" : " We are aware that there was a short-term supply issue which may have affected the availability in May 2018. This was because one of the main suppliers experienced delays in delivery, resulting in a short term out of stock period. Although supplies continued to remain available from other suppliers, we are aware that some may have struggled to support the increase in demand at short notice. The delivery issues were resolved quickly and the overall supply of buprenorphine tablets improved shortly afterwards.<\/p> Since this period, the Department has remained in regular contact with all United Kingdom licensed suppliers of buprenorphine and has been working closely with them to monitor their supply position. Based on these conversations, we have been assured that the available supplies are sufficient to meet the usual UK requirements for this drug. The Department continues to monitor this very closely to ensure that there is consistent and adequate supply of this medication across the country.<\/p> The Department is aware that since this short-term supply issue, the market price has increased. This increased purchase price is reflected in the reimbursement price paid to pharmacies, to ensure that supplies remain available to patients. The market for buprenorphine has generally been competitive and we expect the supply situation to improve over the coming weeks which is likely to result in an increasingly competitive market.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
}
, "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
, "dateOfAnswer" : {"_value" : "2018-10-17", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-10-17T15:25:57.393Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-10-09", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Buprenorphine"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty's Government what action they are taking (1) to remedy any buprenorphine shortage, and (2) to ensure that in the long term there is consistent and adequate supply of this medication, that it is available across the country and is not subject to unpredictable price fluctuations.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1138", "label" : {"_value" : "Biography information for Lord Carlile of Berriew"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Carlile of Berriew"}
], "uin" : "HL10468"}
, {"_about" : "http://data.parliament.uk/resources/984266", "AnsweringBody" : [{"_value" : "Department for Digital, Culture, Media and Sport"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/984266/answer", "answerText" : {"_value" : "As arm\u2019s length bodies, DCMS-sponsored museums determine their own operational matters, including the decision to charge fees for re-use of images of items in their collections - this is an operational policy matter that therefore sits with the institutions themselves. As such it is not appropriate for Government to intervene in these matters and therefore no assessment has been made, or guidance provided, on image re-use. We are currently in the process of revising performance indicators for all fifteen of the DCMS sponsored museums. We are reviewing a broad range of museum activity and government policy in order to inform our decision around which performance indicators will be selected for inclusion in the museum management agreements from 2020. We are not in a position, at this stage, to comment on specific performance indicators as the project is ongoing. The National Archives has published guidance for public sector bodies on complying with the Re-use of Public Sector Information Regulations 2015, including the attached guidance specifically for the culture sector, which can also be found here: http://www.nationalarchives.gov.uk/documents/information-management/psi-implementation-guidance-cultural-sector.pdf<\/a> It is each Accounting Officer's responsibility to ensure that their organisation is compliant with the terms and principles of Managing Public Money. DCMS has a governance framework in place and regularly engages with its arm\u2019s length bodies regarding compliance issues. "}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4247", "label" : {"_value" : "Biography information for Lord Ashton of Hyde"}
}
, "answeringMemberPrinted" : {"_value" : "Lord Ashton of Hyde"}
, "attachment" : {"_about" : "http://data.parliament.uk/resources/984266/answer/attachment/1", "fileName" : {"_value" : "psi-implementation-guidance-cultural-sector.pdf"}
, "title" : "Guidance - the Re-use of Public Sector Information"}
, "dateOfAnswer" : {"_value" : "2018-10-15", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "HL10408"}
, {"_value" : "HL10409"}
, {"_value" : "HL10410"}
, {"_value" : "HL10411"}
, {"_value" : "HL10412"}
, {"_value" : "HL10413"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-10-15T16:44:12.99Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "10"}
, "answeringDeptShortName" : {"_value" : "Digital, Culture, Media and Sport"}
, "answeringDeptSortName" : {"_value" : "Digital, Culture, Media and Sport"}
, "date" : {"_value" : "2018-10-09", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Museums and Galleries: Copyright"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty's Government how their policy to exploit commercially images of works of art in national museums and galleries fits with the mandates of the Arts and Humanities Research Council and other research bodies to make all publicly funded and Research Excellence Framework qualifying scholarship available on open licences from 2020 onwards.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/2593", "label" : {"_value" : "Biography information for Lord Freyberg"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Freyberg"}
], "uin" : "HL10474"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&houseId=2&max-answer.questionFirstAnswered.=2018-10-18T09%3A13%3A48.077Z", "page" : 0, "startIndex" : 1, "totalResults" : 32104, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}